

Joan T Merrill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4556753/publications.pdf>

Version: 2024-02-01

167
papers

18,712
citations

44069

48
h-index

12272

133
g-index

175
all docs

175
docs citations

175
times ranked

13790
citing authors

#	ARTICLE	IF	CITATIONS
1	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
2	A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011, 63, 3918-3930.	6.7	1,277
3	Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITCAM, PTK, KIAA1542 and other loci. <i>Nature Genetics</i> , 2008, 40, 204-210.	21.4	1,192
4	Efficacy and safety of rituximab in moderately to severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. <i>Arthritis and Rheumatism</i> , 2010, 62, 222-233.	6.7	1,111
5	Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis. <i>New England Journal of Medicine</i> , 2005, 353, 2219-2228.	27.0	991
6	Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2005, 353, 2550-2558.	27.0	962
7	Anifrolumab, an Anti-Interferon-Î± Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017, 69, 376-386.	5.6	634
8	The Effect of Combined Estrogen and Progesterone Hormone Replacement Therapy on Disease Activity in Systemic Lupus Erythematosus: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2005, 142, 953.	3.9	539
9	A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 61, 1168-1178.	6.7	515
10	Sifalimumab, an anti-interferon-Î± monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1909-1916.	0.9	420
11	Novel evidence-based systemic lupus erythematosus responder index. <i>Arthritis and Rheumatism</i> , 2009, 61, 1143-1151.	6.7	397
12	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1706-1713.	0.9	391
13	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016, 55, 252-262.	1.9	370
14	Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2002, 46, 3251-3258.	6.7	321
15	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017, 8, 16021.	12.8	314
16	A Phase II study of the efficacy and safety of rontalizumab (rhuMab interferon-Î±) in patients with systemic lupus erythematosus (ROSE). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 196-202.	0.9	302
17	Safety profile and clinical activity of sifalimumab, a fully human anti-interferon-Î± monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1905-1913.	0.9	205
18	Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. <i>Nature Reviews Rheumatology</i> , 2020, 16, 581-589.	8.0	203

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2018, 70, 266-276.	5.6	184
20	Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2014, 41, 300-309.	2.0	149
21	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1502-1509.	0.9	143
22	Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. <i>Lupus Science and Medicine</i> , 2016, 3, e000131.	2.7	118
23	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2016, 68, 1290-1300.	5.6	114
24	Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 534-542.	0.9	111
25	Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1752-1757.	0.9	110
26	Renal involvement in lupus is characterized by unique DNA methylation changes in naïve CD4+ T cells. <i>Journal of Autoimmunity</i> , 2015, 61, 29-35.	6.5	109
27	Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 883-889.	0.9	107
28	The genetics of systemic lupus erythematosus and implications for targeted therapy. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, i37-i43.	0.9	100
29	Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 3364-3373.	6.7	100
30	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1837-1847.	5.6	98
31	Epigenetic Reprogramming in Naive CD4+ T Cells Favoring T Cell Activation and Non-Th1 Effector T Cell Immune Response as an Early Event in Lupus Flares. <i>Arthritis and Rheumatology</i> , 2016, 68, 2200-2209.	5.6	88
32	Anti-β ₂ -Glycoprotein I and Antiphosphatidylserine Antibodies Are Predictors of Arterial Thrombosis in Patients With Antiphospholipid Syndrome. <i>American Journal of Clinical Pathology</i> , 2004, 121, 142-149.	0.7	86
33	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. <i>Arthritis and Rheumatism</i> , 2013, 65, 2887-2897.	6.7	84
34	DNA methylation patterns in naïve CD4+ T cells identify epigenetic susceptibility loci for malar rash and discoid rash in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2015, 2, e000101.	2.7	83
35	Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity. <i>Arthritis and Rheumatology</i> , 2016, 68, 2492-2502.	5.6	79
36	Proinflammatory Adaptive Cytokine and Shed Tumor Necrosis Factor Receptor Levels Are Elevated Preceding Systemic Lupus Erythematosus Disease Flare. <i>Arthritis and Rheumatology</i> , 2014, 66, 1888-1899.	5.6	77

#	ARTICLE	IF	CITATIONS
37	The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. <i>Human Molecular Genetics</i> , 2015, 24, 582-596.	2.9	74
38	Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1125-1134.	5.6	74
39	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1530-1536.	0.9	70
40	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019, 71, 893-902.	3.4	70
41	Lupus community panel proposals for optimising clinical trials: 2018. <i>Lupus Science and Medicine</i> , 2018, 5, e000258.	2.7	62
42	Enhancement of Protein S Anticoagulant Function by Î2-glycoprotein I, a Major Target Antigen of Antiphospholipid Antibodies. <i>Thrombosis and Haemostasis</i> , 1999, 81, 748-757.	3.4	60
43	B lymphocyte stimulator levels in systemic lupus erythematosus: Higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels. <i>Arthritis and Rheumatism</i> , 2011, 63, 3931-3941.	6.7	59
44	Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab. <i>Arthritis and Rheumatology</i> , 2017, 69, 643-654.	5.6	58
45	Which outcome measures in SLE clinical trials best reflect medical judgment?. <i>Lupus Science and Medicine</i> , 2014, 1, e000005.	2.7	56
46	Longitudinal profiling of human blood transcriptome in healthy and lupus pregnancy. <i>Journal of Experimental Medicine</i> , 2019, 216, 1154-1169.	8.5	56
47	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1478-1487.	3.4	55
48	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 281-289.	5.6	55
49	Evidence for gene-gene epistatic interactions among susceptibility loci for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 485-492.	6.7	53
50	IgG Autoantibodies against Î2-Glycoprotein I Complexed with a Lipid Ligand Derived from Oxidized Low-Density Lipoprotein are Associated with Arterial Thrombosis in Antiphospholipid Syndrome. <i>Clinical and Developmental Immunology</i> , 2003, 10, 203-211.	3.3	52
51	Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2018, 5, e000284.	2.7	51
52	Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys. <i>Nature Reviews Rheumatology</i> , 2014, 10, 23-34.	8.0	50
53	Treatment of systemic lupus erythematosus patients with the BAFF antagonist ðceptibody-blisibimod (AMC 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. <i>Arthritis Research and Therapy</i> , 2015, 17, 215.	3.5	48
54	Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate <sc>AMC</sc> 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1071-1076.	5.6	47

#	ARTICLE	IF	CITATIONS
55	Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study. <i>EClinicalMedicine</i> , 2020, 20, 100291.	7.1	47
56	Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. <i>Human Molecular Genetics</i> , 2018, 27, 3813-3824.	2.9	43
57	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 370-378.	0.9	42
58	Contribution of Socioeconomic Status to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes Among Women With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018, 70, 230-235.	3.4	41
59	Antibodies directed to protein S in patients with systemic lupus erythematosus: prevalence and clinical significance. <i>Thrombosis and Haemostasis</i> , 2003, 90, 636-641.	3.4	40
60	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016, 68, 1932-1944.	5.6	40
61	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 356-362.	0.9	40
62	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 67-77.	5.6	39
63	Impact of heart rate variability, a marker for cardiac health, on lupus disease activity. <i>Arthritis Research and Therapy</i> , 2016, 18, 197.	3.5	38
64	Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 951-961.	0.9	38
65	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018, 57, 677-687.	1.9	37
66	Low frequency of flares during pregnancy and post-partum in stable lupus patients. <i>Arthritis Research and Therapy</i> , 2020, 22, 52.	3.5	37
67	The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials. <i>Arthritis and Rheumatology</i> , 2017, 69, 1257-1266.	5.6	36
68	Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. <i>Lupus</i> , 2021, 30, 1254-1263.	1.6	36
69	Challenges in bringing the bench to bedside in drug development for sle. <i>Nature Reviews Drug Discovery</i> , 2004, 3, 1036-1046.	46.4	35
70	How should lupus flares be measured? Deconstruction of the Safety of Estrogen in Lupus Erythematosus National Assessmentâ€“Systemic Lupus Erythematosus Disease Activity Index flare index. <i>Rheumatology</i> , 2014, 53, 2175-2181.	1.9	35
71	Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls. <i>Arthritis Care and Research</i> , 2017, 69, 1780-1788.	3.4	34
72	A plausibly causal functional lupus-associated risk variant in the STAT1â€“STAT4 locus. <i>Human Molecular Genetics</i> , 2018, 27, 2392-2404.	2.9	34

#	ARTICLE	IF	CITATIONS
73	Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes. <i>Arthritis and Rheumatology</i> , 2016, 68, 1964-1969.	5.6	33
74	Pathways of impending disease flare in African-American systemic lupus erythematosus patients. <i>Journal of Autoimmunity</i> , 2017, 78, 70-78.	6.5	33
75	Attainment of treat-to-target endpoints in SLE patients with high disease activity in the ataccept phase 2b ADDRESS II study. <i>Rheumatology</i> , 2020, 59, 2930-2938.	1.9	33
76	Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated subjects with incomplete lupus. <i>Lupus Science and Medicine</i> , 2017, 4, e000176.	2.7	31
77	Antiglutamate Receptor Antibodies and Cognitive Impairment in Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2016, 7, 5.	4.8	30
78	SARS-CoV-2 vaccines in patients with SLE. <i>Lupus Science and Medicine</i> , 2021, 8, e000479.	2.7	30
79	Co-stimulatory molecules as targets for treatment of lupus. <i>Clinical Immunology</i> , 2013, 148, 369-375.	3.2	29
80	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020, 106, 102340.	6.5	27
81	Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1419-1433.	2.9	27
82	Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments. <i>Lupus Science and Medicine</i> , 2015, 2, e000075-e000075.	2.7	26
83	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020, 72, 658-666.	5.6	26
84	Selection of a gene for apolipoprotein a1 using autoantibodies from a patient with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1995, 38, 1655-1659.	6.7	25
85	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1297-1307.	5.6	25
86	Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures. <i>Lupus Science and Medicine</i> , 2019, 6, e000365.	2.7	23
87	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020, 72, 1800-1808.	3.4	23
88	Why, why, why de-lupus (does so badly in clinical trials). <i>Expert Review of Clinical Immunology</i> , 2016, 12, 95-98.	3.0	22
89	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1231-1235.	3.4	22
90	Prognostic significance of repeat biopsy in lupus nephritis: Histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. <i>Clinical Immunology</i> , 2017, 185, 3-9.	3.2	18

#	ARTICLE	IF	CITATIONS
91	Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. <i>Lupus Science and Medicine</i> , 2018, 5, e000263.	2.7	18
92	A 2014 update on the management of patients with systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, e1-e2.	3.4	17
93	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 1734-1740.	5.6	17
94	Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1562-1567.	1.2	17
95	Decreased <i>SMG7</i> expression associates with lupus-risk variants and elevated antinuclear antibody production. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2007-2013.	0.9	16
96	Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. <i>Rheumatology</i> , 2018, 57, 125-133.	1.9	15
97	Measuring disease activity in SLE is an ongoing struggle. <i>Nature Reviews Rheumatology</i> , 2019, 15, 194-195.	8.0	15
98	Immune Response to <i>Enterococcus gallinarum</i> in Lupus Patients Is Associated With a Subset of Lupus-Associated Autoantibodies. <i>Frontiers in Immunology</i> , 2021, 12, 635072.	4.8	15
99	Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100117.	4.0	15
100	Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 962-969.	0.9	15
101	Immunologic findings precede rapid lupus flare after transient steroid therapy. <i>Scientific Reports</i> , 2019, 9, 8590.	3.3	14
102	Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers. <i>Lupus Science and Medicine</i> , 2020, 7, e000360.	2.7	14
103	Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 456-464.	2.0	13
104	Comparison of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus to More Complex Disease Activity Instruments As Evaluated by Clinical Investigators or Real-World Clinicians. <i>Arthritis Care and Research</i> , 2018, 70, 1058-1063.	3.4	13
105	Development and content validity of the Lupus Foundation of America rapid evaluation of activity in lupus (LFA-REAL [®]): a patient-reported outcome measure for lupus disease activity. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 99.	2.4	13
106	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , 2021, 73, 1789-1795.	3.4	13
107	Biological impact of iberdomide in patients with active systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1136-1142.	0.9	13
108	A highlight from the LUPUS 2014 meeting: eight great ideas. <i>Lupus Science and Medicine</i> , 2015, 2, e000087.	2.7	12

#	ARTICLE	IF	CITATIONS
109	Trans-Ethnic Mapping of BANK1 Identifies Two Independent SLE-Risk Linkage Groups Enriched for Co-Transcriptional Splicing Marks. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2331.	4.1	12
110	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1010-1012.	0.9	12
111	The antiphospholipid syndrome and atherosclerosis: Clue to pathogenesis. <i>Current Rheumatology Reports</i> , 2003, 5, 401-406.	4.7	11
112	Differential Expression of the Transcription Factor ARID3a in Lupus Patient Hematopoietic Progenitor Cells. <i>Journal of Immunology</i> , 2015, 194, 940-949.	0.8	11
113	Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial. <i>Lupus Science and Medicine</i> , 2017, 4, e000206.	2.7	11
114	Safety and clinical activity of atacept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 5379-5389.	1.9	11
115	Antibodies to periodontogenic bacteria are associated with higher disease activity in lupus patients. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 106-111.	0.8	11
116	Treatment of systemic lupus erythematosus: a 2012 update. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2012, 70, 172-6.	0.7	11
117	Dehydroepiandrosterone, a sex steroid metabolite in development for systemic lupus erythematosus. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 1017-1025.	4.1	10
118	Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus. <i>Clinical Immunology</i> , 2015, 161, 157-162.	3.2	10
119	Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 242-252.	0.9	10
120	Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design. <i>Arthritis and Rheumatology</i> , 2017, 69, 785-790.	5.6	10
121	New Trials in Lupus and where Are we Going. <i>Current Rheumatology Reports</i> , 2018, 20, 34.	4.7	10
122	Is SLE many single-organ diseases or an overlapping spectrum?. <i>Nature Reviews Rheumatology</i> , 2015, 11, 385-386.	8.0	9
123	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , 2020, , .	3.4	9
124	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1143-1150.	0.9	9
125	Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2022, 74, 1822-1828.	3.4	9
126	Do antiphospholipid antibodies develop for a purpose?. <i>Current Rheumatology Reports</i> , 2006, 8, 109-113.	4.7	8

#	ARTICLE	IF	CITATIONS
127	What does the death of Riquentâ„¸ hold for the future of SLE?. <i>Nature Reviews Rheumatology</i> , 2009, 5, 306-307.	8.0	8
128	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019, 58, 1259-1267.	1.9	8
129	Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical Studies. <i>Arthritis Care and Research</i> , 2020, , .	3.4	8
130	Diagnosis of the antiphospholipid syndrome: How far to go?. <i>Current Rheumatology Reports</i> , 2004, 6, 469-472.	4.7	7
131	SLE clinical trials: impact of missing data on estimating treatment effects. <i>Lupus Science and Medicine</i> , 2019, 6, e000348.	2.7	7
132	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021, 73, 2293-2302.	5.6	7
133	Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials. <i>Lupus Science and Medicine</i> , 2018, 5, e000266.	2.7	6
134	What Did Not Work: The Drug or the Trial?. <i>Arthritis and Rheumatology</i> , 2021, 73, 1773-1775.	5.6	6
135	Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort. <i>Lupus Science and Medicine</i> , 2020, 7, e000419.	2.7	6
136	98â€¸...Results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAbâ€¸5871, in systemic lupus erythematosus (SLE). , 2019, , .		5
137	Regulation of the vasculature: clues from lupus. <i>Current Opinion in Rheumatology</i> , 2002, 14, 504-509.	4.3	4
138	Antiphospholipid syndrome: Whatâ€™s new in understanding antiphospholipid antibody-related stroke?. <i>Current Rheumatology Reports</i> , 2006, 8, 159-161.	4.7	4
139	What was wrong and might now go right with clinical trials for lupus?. <i>Current Rheumatology Reports</i> , 2009, 11, 235-237.	4.7	4
140	FRIO176â€¸...PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF A REVERSIBLE B CELL INHIBITOR, XMABâ€¸5871, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). , 2019, , .		4
141	Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura. <i>PLoS ONE</i> , 2015, 10, e0117614.	2.5	4
142	Clinical trials for lupus--are we there yet?. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2009, 67, 267-70.	0.7	4
143	Ending the 50-year drought of FDA drug approval for SLE. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2011, 69, 238-42.	0.7	4
144	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021, 30, 096120332110142.	1.6	3

#	ARTICLE	IF	CITATIONS
145	Emergence of targeted immune therapies for systemic lupus. Expert Opinion on Emerging Drugs, 2005, 10, 53-65.	2.4	2
146	Editorial: Lupus, the Chameleon: Many Disguises Difficult to Capture. Arthritis and Rheumatology, 2017, 69, 1921-1924.	5.6	1
147	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Research and Therapy, 2017, 19, 287.	3.5	1
148	Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders. Frontiers in Immunology, 2020, 11, 592639.	4.8	1
149	A review of the obstetrics literature and the first novel treatment on the horizon. Current Rheumatology Reports, 2002, 4, 377-378.	4.7	0
150	Is individualized medicine on the horizon for lupus?. Current Rheumatology Reports, 2008, 10, 257-258.	4.7	0
151	Chapter 14 Antiphospholipid Antibodies and Atherosclerosis. Handbook of Systemic Autoimmune Diseases, 2009, 10, 169-183.	0.1	0
152	T Cell Targeted Therapies in Lupus: Do They Make Sense?. Current Treatment Options in Rheumatology, 2015, 1, 19-29.	1.4	0
153	CS-07â€¦Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
154	CT-06â€¦Missing outcomes in SLE clinical trials: impact on estimating treatment effects. , 2018, , .		0
155	209â€¦Attainment of low disease activity and remission with atacicept in patients with systemic lupus erythematosus and high disease activity in the phase IIb ADDRESS II study and its long-term extension. , 2019, , .		0
156	21â€¦Is lupus nephritis onset delayed in older caucasian females with less aggressive pathology?. , 2019, , .		0
157	233â€¦Autoantibody-positive healthy individuals constrain T cell pathways to regulate autoimmune disease. , 2019, , .		0
158	296â€¦Activated stress response genes and perturbation of regulatory pathways in anti-nuclear antibody positive individuals and SLE patients vary by cell type and race in single-cell transcriptomic analyses. , 2019, , .		0
159	Challenges of systemic lupus clinical trials. , 2021, , 673-682.		0
160	Elevated Serum Type I Interferon Activity and Type I Interferon Peripheral Blood Gene Signature In a Subset of Patients with Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura.. Blood, 2010, 116, 3694-3694.	1.4	0
161	Inhibitory Autoantibodies to Protein Disulfide Isomerase From Systemic Lupus Erythematosus Patients Are Prothrombotic. Blood, 2012, 120, 392-392.	1.4	0
162	Systemic Lupus Erythematosus, Clinical Trials. , 2014, , 1156-1161.		0

#	ARTICLE	IF	CITATIONS
163	1124...Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach. , 2021, , .		0
164	1107...Economic evaluation of hydroxychloroquine use in an international inception cohort. , 2021, , .		0
165	801...Factors associated with SLE flares after HCQ taper, discontinuation or maintenance in the SLICC inception cohort: lower education linked with higher flare risk. , 2021, , .		0
166	1704...Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
167	Reply. Arthritis and Rheumatology, 2022, 74, 1093-1093.	5.6	0